CP-380736

CAS No. 179688-29-0

CP-380736( CP 380736,CP380736,PF-00520893 )

Catalog No. M22865 CAS No. 179688-29-0

CP-380736 is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a tyrosine kinase that activates MAPK, JNK, and Akt pathways, and is an important mediator of several types of cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
25MG 41 In Stock
50MG 60 In Stock
100MG 90 In Stock
200MG 129 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CP-380736
  • Note
    Research use only, not for human use.
  • Brief Description
    CP-380736 is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a tyrosine kinase that activates MAPK, JNK, and Akt pathways, and is an important mediator of several types of cancer.
  • Description
    CP-380736 is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a tyrosine kinase that activates MAPK, JNK, and Akt pathways, and is an important mediator of several types of cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CP 380736,CP380736,PF-00520893
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    179688-29-0
  • Formula Weight
    294.3
  • Molecular Formula
    C14H18N2O5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:Soluble
  • SMILES
    COCCOC1=C(C=C2C(=C1)C(=O)NC=N2)OCCOC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • ICA-105574

    ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.

  • Selatinib

    Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.

  • Rezivertinib

    Rezivertinib (BPI-7711) is an orally available, selective and potent inhibitor of tyrosine kinase (EGFR) with antitumor activity for central nervous system disorders.